 13. Concurrent disease or condition that would interfere with study participation or safety, such as any of the following: Active, clinically significant infection either grade 2 by National Cancer Institute NCI Common Terminology Criteria for Adverse Events CTCAE v4.03 or requiring the use of parenteral anti-microbial agents within 14 days before Day 1 of study drug Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders Non-healing wound, ulcer, or bone fracture 